|
Jun 25
|
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
|
|
May 26
|
Those who invested in Aquestive Therapeutics (NASDAQ:AQST) three years ago are up 128%
|
|
May 14
|
Aquestive Therapeutics Inc (AQST) Q1 2025 Earnings Call Highlights: Navigating Revenue Declines ...
|
|
Apr 14
|
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
|
|
Feb 13
|
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
|
|
Feb 12
|
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
|
|
Sep 30
|
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
|
|
Sep 27
|
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
|
|
Aug 8
|
Aquestive Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
|
Aug 6
|
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Aug 6
|
Aquestive Therapeutics: Q2 Earnings Snapshot
|
|
Jul 30
|
Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$72m last week but retail investors profited the most
|
|
Jul 25
|
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
|
|
Jul 23
|
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
|
|
Jun 25
|
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
|
|
Jun 25
|
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
|
|
Jun 19
|
Investors in Aquestive Therapeutics (NASDAQ:AQST) have unfortunately lost 36% over the last five years
|
|
Jun 18
|
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
|
|
May 9
|
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
|